EXPRESSION OF LEWIS-RELATED ANTIGEN AND PROGNOSIS IN STAGE-I NONSMALL CELL LUNG-CANCER

被引:40
|
作者
OGAWA, J
SANO, A
INOUE, H
KOIDE, S
机构
[1] First Department of Surgery, School of Medicine, Tokai University, Kanagawa
来源
ANNALS OF THORACIC SURGERY | 1995年 / 59卷 / 02期
关键词
D O I
10.1016/0003-4975(94)00866-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Immunohistochemical expression of Lewis(y), sialyl Lewis(x), and sialyl Lewis(a) were examined in relation to blood vessel invasion and prognosis in 133 patients with stage I non-small cell lung cancer who had a curative resection from 1980 to 1991. Expression of sialyl Lewis(x) in adenocarcinomas was higher than in squamous cell and large cell carcinomas, and Lewis(y) immunoreactivity was the highest among the three antigens. The frequency of blood vessel invasion was significantly higher in tumors with expression of Lewis(y) or sialyl Lewis antigen (sialyl Lewis(y) or sialyl Lewis(a)), however, Lewis(y) expression was even more significant. The postoperative survival was significantly shorter when tumors expressed both the Lewis(y) and sialyl Lewis antigen. However, the survival of patients with either Lewis(y) or sialyl Lewis antigen expression was similar to that of patients whose tumors did not express either the Lewis(y) or sialyl Lewis antigens. These results suggest that Lewis(y) and sialyl Lewis antigen may be of prognostic value for metastatic potential but have different functional roles in tumor cells.
引用
收藏
页码:412 / 415
页数:4
相关论文
共 50 条
  • [41] PROGNOSTIC FACTORS IN NONSMALL CELL LUNG-CANCER
    FELD, R
    BORGES, M
    GINER, V
    GINSBERG, R
    HARPER, P
    KLASTERSKY, J
    LACQUET, L
    PAESMANS, M
    PAYNE, D
    ROSELL, R
    SAUSE, W
    SCULIER, JP
    SHAW, E
    SORENSEN, JB
    SPLINTER, T
    STAHEL, R
    BUNN, P
    LUNG CANCER, 1994, 11 : S19 - S23
  • [42] RESULTS OF SURGICAL-TREATMENT OF STAGE IIIA NONSMALL CELL LUNG-CANCER
    CANGEMI, V
    VOLPINO, P
    DANDREA, N
    CHIAROTTI, F
    TOMASSINI, R
    PIAT, G
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 1995, 9 (07) : 352 - 359
  • [43] COMBINED CHEMORADIOTHERAPY IN STAGE IIIA, IIIB NONSMALL CELL LUNG-CANCER (NSCLC)
    PANOUSAKI, E
    PANTELAKOS, P
    KARPASITIS, N
    SAMANTAS, E
    ZABOGLOU, N
    SKARLOS, DV
    JOURNAL OF CHEMOTHERAPY, 1993, 5 : 706 - 706
  • [44] CONCOMITANT CHEMORADIOTHERAPY FOR NONSMALL CELL LUNG-CANCER
    VOKES, EE
    HARAF, DJ
    HOFFMAN, PC
    BITRAN, JD
    FERGUSON, MK
    GOLOMB, HM
    LUNG CANCER, 1994, 10 : S253 - S261
  • [45] CHEMORADIATION IN ADVANCED NONSMALL CELL LUNG-CANCER
    PISCH, J
    BERSON, AM
    MALAMUD, S
    BEATTIE, EJ
    HARVEY, J
    VIKRAM, B
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 33 (01): : 183 - 188
  • [46] INTRAOPERATIVE BRACHYTHERAPY IN NONSMALL CELL LUNG-CANCER
    NORI, D
    SEMINARS IN SURGICAL ONCOLOGY, 1993, 9 (02): : 99 - 107
  • [47] MULTIMODALITY THERAPY OF NONSMALL CELL LUNG-CANCER
    MCCARLEY, D
    CANCER RESEARCH THERAPY & CONTROL, 1993, 3 (03): : 197 - 201
  • [48] IS CHEMOTHERAPY FOR NONSMALL CELL LUNG-CANCER WORTHWHILE
    COATES, A
    FORBES, J
    LANCET, 1993, 342 (8862): : 4 - 4
  • [49] EDATREXATE STUDIES IN NONSMALL CELL LUNG-CANCER
    GRALLA, RJ
    LUNG CANCER, 1995, 12 : S187 - S191
  • [50] ADJUVANT CHEMOTHERAPY FOR NONSMALL CELL LUNG-CANCER
    JOHNSON, DH
    CHEST, 1994, 106 (06) : S313 - S317